{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000066","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.384731+00:00","generated_at":"2026-06-15T10:20:50.436153+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance","bullets":["Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.","Net loss $16.8M ($0.12 per share); cash & investments $95.1M at March 31, 2023.","2023 guidance: revenue $135M-$165M; cash from ops ($57M)-($77M); year-end cash $45M-$65M.","Announced XeriJect collaboration with Regeneron for two undisclosed monoclonal antibodies.","Appointed Ricki Fairley to Board of Directors, increasing board to nine members."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000066","json":"https://secwatch.observer/filing/0001867096-23-000066.json","markdown":"https://secwatch.observer/filing/0001867096-23-000066.md","text":"https://secwatch.observer/filing/0001867096-23-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/0001867096-23-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/xers-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T10:20:50.436153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99f05388f5a8b69f2ac0c496ba8447dbb127158a","claim":"Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $33.2M, net income $16.8 million, EPS $0.12 per share. Guidance reaffirmed.","evidence_excerpt":"forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/0001867096-23-000066-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$33.2M"},{"label":"Net income","value":"$16.8 million"},{"label":"EPS","value":"$0.12 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}